FENC

Fennec Pharmaceuticals Inc. (FENC) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Fennec Pharmaceuticals is a commercial-stage biopharmaceutical company focused on PEDMARK (sodium thiosulfate injection), the first and only FDA-approved therapy to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. The company also holds an exclusive license with Norgine Pharma to commercialize the product (branded as PEDMARQSI) in Europe, Australia, and New Zealand.

Key Financial Metrics (Six Months Ended June 30, 2025)

Material Changes vs. Prior Period

• Revenue: Total revenue decreased by $14.2 million (44%) compared to the six months ended June 30, 2024. This decline is primarily due to the absence of $17.96 million in licensing revenue recognized in Q1 2024 from the Norgine agreement. However, net product sales for PEDMARK increased by $3.7 million (25%) to $18.4 million, driven by expanded market penetration and focus on the adolescent and young adult (AYA) population.
• Profitability: The company reported a net loss of $4.3 million for the six months ended June 30, 2025, compared to a net income of $7.3 million in the same period in 2024. The shift from income to loss is attributable to the one-time licensing revenue in 2024 and increased operating expenses.
• Expenses: Selling and marketing expenses decreased by $2.6 million year-over-year, largely due to the elimination of European pre-commercial activities following the Norgine transaction. General and administrative expenses increased by $0.4 million, driven by higher headcount, consulting costs, and intellectual property litigation expenses.
• Debt: Interest expense decreased by $0.9 million due to a debt paydown of $13 million in December 2024. As of June 30, 2025, outstanding notes total approximately $19.5 million (including PIK interest).
• Liquidity: Cash and cash equivalents decreased by $7.9 million from the beginning of the year, primarily due to seasonal operating expenses and working capital timing, despite the cash burn from operations.

Outlook, Risks, and Contingencies

• Liquidity Outlook: Management believes current funds, bolstered by the upfront payment from the Norgine agreement, are sufficient to fund operations for at least the next 12 months.
• Patent Litigation (CIPLA): The company is engaged in ongoing patent infringement litigation against CIPLA Ltd. regarding a generic version of PEDMARK. CIPLA filed an ANDA with Paragraph IV certifications. Fennec has secured Orphan Drug Exclusivity until September 20, 2029, which blocks FDA approval of the generic. The court recently consolidated cases and adopted Fennec's proposed claim constructions. The suit remains ongoing.
• Commercialization: Norgine launched PEDMARQSI in Germany and the U.K. in early 2025. Fennec continues to expand its U.S. sales force and patient access programs.
• Stock-Based Compensation: The company recognized $2.3 million in stock-based compensation expense for the six-month period. A new performance-based unit (PSU) grant was approved in May 2025 tied to revenue milestones.

Key Investor Verification Points

• Revenue Sustainability: Verify the trajectory of PEDMARK product sales growth to ensure it can offset the absence of large, one-time licensing revenues seen in 2024.
• Cash Burn Rate: Monitor the negative operating cash flow of $8.0 million for the six-month period against the $18.7 million cash balance to assess runway duration.
• Debt Obligations: Review the terms of the remaining $19.5 million in convertible notes, including the 12% interest rate and maturity date of August 2027.
• Litigation Status: Track the progress of the CIPLA litigation, as a loss could impact market exclusivity and future revenue streams, despite the Orphan Drug Exclusivity protection until 2029.
• Allowance for Credit Losses: Note the $4.3 million allowance for credit losses recorded against accounts receivable, reflecting potential collection risks with distributors.